Nav: Home

Patients bear increased financial burden for growth hormone treatment despite FDA approval

March 24, 2019

Philadelphia, March 24, 2019--Despite an FDA approval of growth hormone treatment for children with idiopathic short stature (ISS), the mean cost burden to patients and their families has increased over time, according to findings from researchers at Children's Hospital of Philadelphia (CHOP) and the Leonard Davis Institute of Health Economics (LDI) of the University of Pennsylvania. The findings were presented during ENDO 2019 in New Orleans, LA.

Study findings indicate that increased patient cost-sharing and coverage restrictions are responsible for a greater cost burden that is placed on families and not necessarily insurance companies, which have seen decreased growth hormone costs per patient over the same period of time.

Growth hormone was approved by the U.S. Food and Drug Administration (FDA) for the treatment of ISS in 2003. This increased the potential availability of growth hormone from one in 3,500 children with growth hormone decificienty to the shortest 1.2 percent of the US population. However, over the last decade, insurance companies have instituted progressive restrictions on coverage of growth hormone, including adopting formulary preference strategies and more strict plan-specific critera for coverage, as well as denying any covering of growth hormone for ISS treatment.

"Because growth hormone is a very expensive medication that requires years of daily injections, cost-containment efforts by insurance providers have increasingly encroached upon and eroded patient-physician decision making autonomy and clinical care," said Adda Grimberg, MD, a pediatric endocrinologist and Scientific Director of the Growth Center at CHOP, Professor of Pediatrics at the Perelman School of Medicine, University of Pennsylvania and lead author of the study. "It was important for us to understand the extent of how these restrictions by insurance companies were impacting families and growth hormone use overall."

Using administrative claims data between 2001 and 2016, the study showed that the number of prescriptions for growth hormone rose from 5.1 patients per 10,000 beneficiaries in 2001 to 14.6 per 10,000 in 2016, although no dramatic change was observed in 2003 when growth hormone received FDA approval for ISS. While total growth hormone expenditures per patient decreased as did the estimated insurance-paid amount, the mean copayments, deductibles and total financial burden to patient families increased by 234 percent in nominal and 161 percent in real dollars. The insurance data also showed an increase in the frequency of switching between growth hormone brands.

"Because the different growth hormone brands use different injection delivery devices, brand switching poses additional patient family burdens: stress and anxiety about the switch and potential for interruptions in treatment, required retraining on the new device or devices, and potential for dosing errors," Grimberg said. "While progressive coverage restrictions and formularies have lowered the total cost and insurer burden of growth hormone treatment, those savings were not passed on to patients."
-end-
Grimberg and Kanter, "Growth Hormone Utilization by U.S. Youth: Trends as Insurance Pushes Back After FDA-approved Expansion." Presented at ENDO 2019, New Orleans, Louisiana, March 23-26, 2019.

About Children's Hospital of Philadelphia: Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals, and pioneering major research initiatives, Children's Hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country. In addition, its unique family-centered care and public service programs have brought the 546-bed hospital recognition as a leading advocate for children and adolescents. For more information, visit http://www.chop.edu

Children's Hospital of Philadelphia

Related Growth Hormone Articles:

Growth hormone plays key role in early puberty, breast cancer risk
Girls who enter puberty early in life--as measured by early breast development and age of first menstrual period--have a longer window of susceptibility to breast cancer.
Human growth hormone treatment after ACL injury may prevent loss of muscle strength
A new study finds the use of HGH treatment in patients that have undergone ACL reconstructive surgery may prevent the loss of muscle strength and weakness.
Liver surgery success boosted by growth hormone
Growth hormone has been identified as playing a key role in reducing inflammation and increasing survival rates following liver surgery.
Growth hormone acts to prevent weight loss
A Brazilian study shows that, like leptin, growth hormone contributes directly to energy conservation when the body loses weight.
Cost savings from growth hormone insurance strategies not passed on to patients
Increasingly aggressive insurance strategies have lowered the total costs and insurance costs of growth hormone drugs, but those savings are not being passed on to patients, according to new research to be presented Sunday at ENDO 2019, the Endocrine Society's annual meeting in New Orleans, La.
Patients bear increased financial burden for growth hormone treatment despite FDA approval
Despite an FDA approval of growth hormone treatment for children with idiopathic short stature (ISS), the mean cost burden to patients and their families has increased over time.
Growth hormone may provide new hope for stroke survivors
Less fatigue and better recovery of cognitive abilities such as learning and memory.
FASEB Science Research Conference: Growth Hormone/Prolactin
This SRC will bring together international scientists from academia and industry for lively discussions on the latest developments in the growth hormone (GH)/prolactin (PRL) family of hormones and their clinical applications.
Low thyroid hormone before birth alters growth and development of fetal pancreas
Levels of thyroid hormone in babies influences insulin-secreting cells of the pancreas, according to a new study published in The Journal of Physiology.
When should doctors treat short children and teens with growth hormone?
When is it appropriate to treat short children with growth hormone?
More Growth Hormone News and Growth Hormone Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: The Power Of Spaces
How do spaces shape the human experience? In what ways do our rooms, homes, and buildings give us meaning and purpose? This hour, TED speakers explore the power of the spaces we make and inhabit. Guests include architect Michael Murphy, musician David Byrne, artist Es Devlin, and architect Siamak Hariri.
Now Playing: Science for the People

#576 Science Communication in Creative Places
When you think of science communication, you might think of TED talks or museum talks or video talks, or... people giving lectures. It's a lot of people talking. But there's more to sci comm than that. This week host Bethany Brookshire talks to three people who have looked at science communication in places you might not expect it. We'll speak with Mauna Dasari, a graduate student at Notre Dame, about making mammals into a March Madness match. We'll talk with Sarah Garner, director of the Pathologists Assistant Program at Tulane University School of Medicine, who takes pathology instruction out of...
Now Playing: Radiolab

What If?
There's plenty of speculation about what Donald Trump might do in the wake of the election. Would he dispute the results if he loses? Would he simply refuse to leave office, or even try to use the military to maintain control? Last summer, Rosa Brooks got together a team of experts and political operatives from both sides of the aisle to ask a slightly different question. Rather than arguing about whether he'd do those things, they dug into what exactly would happen if he did. Part war game part choose your own adventure, Rosa's Transition Integrity Project doesn't give us any predictions, and it isn't a referendum on Trump. Instead, it's a deeply illuminating stress test on our laws, our institutions, and on the commitment to democracy written into the constitution. This episode was reported by Bethel Habte, with help from Tracie Hunte, and produced by Bethel Habte. Jeremy Bloom provided original music. Support Radiolab by becoming a member today at Radiolab.org/donate.     You can read The Transition Integrity Project's report here.